177 related articles for article (PubMed ID: 17520584)
1. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
[TBL] [Abstract][Full Text] [Related]
2. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab and radiotherapy for head and neck cancer.
Posner MR; Wirth LJ
N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
[No Abstract] [Full Text] [Related]
4. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
5. More on cetuximab in head and neck cancer.
Mell LK; Weichselbaum RR
N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
[No Abstract] [Full Text] [Related]
6. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
Teoh DC; Rodger S; Say J; Hartley A
Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
[No Abstract] [Full Text] [Related]
7. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
Burtness B
J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
[No Abstract] [Full Text] [Related]
8. Cetuximab in squamous cell head and neck carcinomas.
Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
[TBL] [Abstract][Full Text] [Related]
9. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Burtness BA
Clin Adv Hematol Oncol; 2008 Oct; 6(10):742-50. PubMed ID: 18997665
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab plus radiotherapy for head and neck cancer.
Armstrong JG
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710907
[No Abstract] [Full Text] [Related]
12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; MartÃn P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
14. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab plus radiotherapy for head and neck cancer.
Cengiz M; Yildiz F; Genc M
N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710908
[No Abstract] [Full Text] [Related]
17. [Recent advances in molecular-targeted drugs in head and neck cancer].
Tahara M
Gan To Kagaku Ryoho; 2008 May; 35(5):745-52. PubMed ID: 18487911
[TBL] [Abstract][Full Text] [Related]
18. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
20. [Monoclonal antibodies for the treatment of head and neck cancer].
Sautois B; Martin M; Demez P; Piret P; Devillers D; Moreau P
Rev Med Liege; 2009; 64(5-6):284-6. PubMed ID: 19642460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
